• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

西班牙区域层面新冠疫苗接种水平与发病率和致死率之间的关联

On the association between COVID-19 vaccination levels and incidence and lethality rates at a regional scale in Spain.

作者信息

Briz-Redón Álvaro, Serrano-Aroca Ángel

机构信息

Department of Statistics and Operations Research, University of Valencia, Valencia, Spain.

Centro de Investigación Traslacional San Alberto Magno, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain.

出版信息

Stoch Environ Res Risk Assess. 2022;36(9):2941-2948. doi: 10.1007/s00477-021-02166-y. Epub 2022 Jan 5.

DOI:10.1007/s00477-021-02166-y
PMID:35002502
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8727484/
Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the coronavirus disease 2019 (COVID-19), has led to the deepest global health and economic crisis of the current century. This dramatic situation has forced the public health authorities and pharmaceutical companies to develop anti-COVID-19 vaccines in record time. Currently, almost 80% of the population are vaccinated with the required number of doses in Spain. Thus, in this paper, COVID-19 incidence and lethality rates are analyzed through a segmented spatio-temporal regression model that allows studying if there is an association between a certain vaccination level and a change (in mean) in either the incidence or the lethality rates. Spatial dependency is included by considering the Besag-York-Mollié model, whereas natural cubic splines are used for capturing the temporal structure of the data. Lagged effects between the exposure and the outcome are also taken into account. The results suggest that COVID-19 vaccination has not allowed yet (as of September 2021) to observe a consistent reduction in incidence levels at a regional scale in Spain. In contrast, the lethality rates have displayed a declining tendency which has associated with vaccination levels above 50%.

摘要

导致2019冠状病毒病(COVID-19)的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引发了本世纪最严重的全球健康和经济危机。这种严峻形势迫使公共卫生当局和制药公司在创纪录的时间内研发抗COVID-19疫苗。目前,西班牙近80%的人口已接种规定剂量的疫苗。因此,本文通过分段时空回归模型分析COVID-19的发病率和致死率,该模型能够研究特定的疫苗接种水平与发病率或致死率的变化(均值)之间是否存在关联。通过考虑贝萨格-约克-莫利模型纳入空间依赖性,而使用自然三次样条来捕捉数据的时间结构。还考虑了暴露与结果之间的滞后效应。结果表明,截至2021年9月,COVID-19疫苗接种尚未在西班牙区域层面使发病率持续下降。相比之下,致死率呈现出下降趋势,这与50%以上的疫苗接种水平相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f1f/8727484/018a5d106c45/477_2021_2166_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f1f/8727484/33812d7fd1ca/477_2021_2166_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f1f/8727484/5f632370eace/477_2021_2166_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f1f/8727484/f9cf74f800a9/477_2021_2166_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f1f/8727484/f77fdbe45327/477_2021_2166_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f1f/8727484/23f98a7b87e4/477_2021_2166_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f1f/8727484/018a5d106c45/477_2021_2166_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f1f/8727484/33812d7fd1ca/477_2021_2166_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f1f/8727484/5f632370eace/477_2021_2166_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f1f/8727484/f9cf74f800a9/477_2021_2166_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f1f/8727484/f77fdbe45327/477_2021_2166_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f1f/8727484/23f98a7b87e4/477_2021_2166_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f1f/8727484/018a5d106c45/477_2021_2166_Fig6_HTML.jpg

相似文献

1
On the association between COVID-19 vaccination levels and incidence and lethality rates at a regional scale in Spain.西班牙区域层面新冠疫苗接种水平与发病率和致死率之间的关联
Stoch Environ Res Risk Assess. 2022;36(9):2941-2948. doi: 10.1007/s00477-021-02166-y. Epub 2022 Jan 5.
2
COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.COVID-19 病例和住院情况按 COVID-19 疫苗接种状况和既往 COVID-19 诊断情况划分-加利福尼亚州和纽约州,2021 年 5 月至 11 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):125-131. doi: 10.15585/mmwr.mm7104e1.
3
Population Mobility Trends, Deprivation Index and the Spatio-Temporal Spread of Coronavirus Disease 2019 in Ireland.人口流动趋势、贫困指数与 2019 年冠状病毒病在爱尔兰的时空传播。
Int J Environ Res Public Health. 2021 Jun 10;18(12):6285. doi: 10.3390/ijerph18126285.
4
Direct and Indirect Effectiveness of mRNA Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 in Long-Term Care Facilities, Spain.mRNA 疫苗对西班牙长期护理机构中严重急性呼吸综合征冠状病毒 2 有效性的直接和间接影响
Emerg Infect Dis. 2021 Oct;27(10):2595-2603. doi: 10.3201/eid2710.211184. Epub 2021 Jul 27.
5
Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?接种 COVID-19 疫苗后,人乳中能否检测到 SARS-CoV-2 抗体?
J Pediatric Infect Dis Soc. 2022 Apr 30;11(4):126. doi: 10.1093/jpids/piac024.
6
Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery.妊娠期 2019 年冠状病毒病(COVID-19)疫苗接种、严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染史和疫苗加强剂与分娩时母婴抗体水平的关系。
Obstet Gynecol. 2022 Mar 1;139(3):373-380. doi: 10.1097/AOG.0000000000004693.
7
Effectiveness of 3 COVID-19 Vaccines in Preventing SARS-CoV-2 Infections, January-May 2021, Aragon, Spain.2021 年 1 月至 5 月,西班牙阿拉贡地区 3 种 COVID-19 疫苗预防 SARS-CoV-2 感染的有效性。
Emerg Infect Dis. 2022 Mar;28(3):591-598. doi: 10.3201/eid2803.212027.
8
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗(灭活,Vero 细胞)有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
9
[Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].[卡斯蒂利亚-莱昂社会医疗中心工作人员接种辉瑞/生物科技公司的BNT162b2 mRNA疫苗后对严重急性呼吸综合征冠状病毒2的体液免疫。]
Rev Esp Salud Publica. 2021 Oct 25;95:e202110141.
10
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.新冠病毒-19(Sars-Cov-2)的英国变体不应造成疫苗问题。
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.

引用本文的文献

1
Stability, homogeneity and measurement uncertainty estimation of PVP-I solutions for the application on oro and nasopharynx against SARS-CoV-2.用于针对 SARS-CoV-2 的口咽和鼻咽应用的 PVP-I 溶液的稳定性、均一性和测量不确定度评估。
Sci Rep. 2024 Mar 27;14(1):7268. doi: 10.1038/s41598-024-52346-3.
2
Exploring the risk factors of COVID-19 Delta variant in the United States based on Bayesian spatio-temporal analysis.基于贝叶斯时空分析探讨美国 COVID-19 Delta 变异株的风险因素。
Transbound Emerg Dis. 2022 Sep;69(5):e2731-e2744. doi: 10.1111/tbed.14623. Epub 2022 Jul 9.
3
A comprehensive account of SARS-CoV-2 genome structure, incurred mutations, lineages and COVID-19 vaccination program.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)基因组结构、发生的突变、谱系及2019冠状病毒病(COVID-19)疫苗接种计划的全面阐述。
Future Virol. 2022 May. doi: 10.2217/fvl-2021-0277. Epub 2022 Jun 16.
4
Prior SARS-CoV-2 infection balances immune responses triggered by four EMA-approved COVID-19 vaccines: An observational study.既往感染严重急性呼吸综合征冠状病毒2型可平衡四种欧洲药品管理局批准的新型冠状病毒肺炎疫苗引发的免疫反应:一项观察性研究。
Clin Transl Med. 2022 May;12(5):e869. doi: 10.1002/ctm2.869.